Tempus Announces Real-World Data-Driven Program to Accelerate Precision Oncology Research
Tempus, a leader in artificial intelligence and precision medicine,announced Tempus+, a proprietary program that powers collaborative precision oncology research through the use of real-world data. The Tempus+ community of researchers already includes a number of medical centers that are leveraging the program to advance its research, including Allegany Health Network, Baylor College of Medicine, Rush University Medical Center, Stanford Cancer Center, TriHealth, UCLA Jonsson Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, and University of North Carolina Lineberger Comprehensive Cancer Center.
Recommended AI News: Darktrace Adds Early Warning System to Antigena Email
“Our clinicians and scientists are excited to use Tempus+ as a platform to complement our internal precision oncology initiatives”
“The Tempus platform is uniquely positioned to provide the resources necessary to create a clear path for collaborative research,” said Mike Thompson, MD, PhD, Vice President of Clinical Partnerships at Tempus. “The institutions that are already leveraging Tempus+ have experienced the program’s ability to accelerate their critical work, and we look forward to seeing it reach its full potential.”
Researchers at participating institutions gain access to Tempus’ library of more than five million de-identified research records through the company’s data analytics platform, Lens, to identify patterns and insights, define and test their hypotheses, and eventually investigate and potentially publish their research. Tempus+ is creating a sustainable and secure infrastructure to collect and analyze the data required to foster research that can inform the future of clinical care.
“With more readily available next-generation sequencing and other molecular profiling technologies, we are gaining increasing insights into the pathogenesis of disease, prognostic stratification, and potentially actionable sarcoma alterations. Tempus+ has one of the largest comprehensive molecular profiling databases of sarcoma across all histologic subtypes and age ranges,” said Noah Federman, MD, Professor and Director of the UCLA Pediatric Sarcoma Program. “I am just so excited to be able to work with Tempus+ and collaborators across the country to be able to interrogate this enormous annotated resource.”
“Today large numbers of cancer patients are having their cancers analyzed for genetic alterations, some of which may drive the tumors’ growth and spread,” said Timothy M. Kuzel, MD, FACP, Division Chief of Hematology/Oncology/Cell Therapy at Rush University Medical Center. “By having access to these large data sets accumulated from hundreds of centers, including clinical data points such as treatments given and the responses they provide, Rush physicians and researchers can use these clues to develop the next generation of treatments for our patients.”
“Our clinicians and scientists are excited to use Tempus+ as a platform to complement our internal precision oncology initiatives,” remarked Quintin Pan, PhD, Deputy Director and Coleman Chair in Cancer Research & Therapeutics at University Hospitals Seidman Cancer Center. “Having access to a robust real-world cancer patient dataset will allow us to better understand how to deliver the best care to every cancer patient at the appropriate time.”
[To share your insights with us, please write to email@example.com]